<code id='5F55620183'></code><style id='5F55620183'></style>
    • <acronym id='5F55620183'></acronym>
      <center id='5F55620183'><center id='5F55620183'><tfoot id='5F55620183'></tfoot></center><abbr id='5F55620183'><dir id='5F55620183'><tfoot id='5F55620183'></tfoot><noframes id='5F55620183'>

    • <optgroup id='5F55620183'><strike id='5F55620183'><sup id='5F55620183'></sup></strike><code id='5F55620183'></code></optgroup>
        1. <b id='5F55620183'><label id='5F55620183'><select id='5F55620183'><dt id='5F55620183'><span id='5F55620183'></span></dt></select></label></b><u id='5F55620183'></u>
          <i id='5F55620183'><strike id='5F55620183'><tt id='5F55620183'><pre id='5F55620183'></pre></tt></strike></i>

          Home / Wikipedia / entertainment

          entertainment


          entertainment

          author:leisure time    Page View:1989
          David L. Ryan/Boston Globe

          A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

          The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

          advertisement

          Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In